These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9300354)

  • 1. On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data.
    Sun H; Ette EI; Ludden TM
    J Pharmacokinet Biopharm; 1996 Dec; 24(6):637-50. PubMed ID: 9300354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of population pharmacokinetic parameters in the presence of non-compliance.
    Mu S; Ludden TM
    J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):53-81. PubMed ID: 12800807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balanced designs in longitudinal population pharmacokinetic studies.
    Ette EI; Sun H; Ludden TM
    J Clin Pharmacol; 1998 May; 38(5):417-23. PubMed ID: 9602953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ignorability and parameter estimation in longitudinal pharmacokinetic studies.
    Ette EI; Sun H; Ludden TM
    J Clin Pharmacol; 1998 Mar; 38(3):221-6. PubMed ID: 9549660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times.
    Knights J; Rohatagi S
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):627-37. PubMed ID: 26209956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.
    Dumont C; Mentré F; Gaynor C; Brendel K; Gesson C; Chenel M
    Clin Pharmacokinet; 2013 Jan; 52(1):43-57. PubMed ID: 23212609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simulation for clinical repeated-dose pharmacokinetic trials applying a peak-and-trough sampling design to estimate oral clearance.
    Ishida K; Kayano Y; Taguchi M; Hashimoto Y
    Biol Pharm Bull; 2007 Nov; 30(11):2159-62. PubMed ID: 17978492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interpretation of simulation studies for efficient estimation of population pharmacokinetic parameters.
    Ette EI; Kelman AW; Howie CA; Whiting B
    Ann Pharmacother; 1993 Sep; 27(9):1034-9. PubMed ID: 8117353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies.
    Ette EI; Howie CA; Kelman AW; Whiting B
    Pharm Res; 1995 May; 12(5):729-37. PubMed ID: 7479560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating the contribution of residual unexplained variability components on bias and imprecision of parameter estimates in population pharmacokinetic mixed-effects modeling.
    Jaber MM; Brundage RC
    J Pharmacokinet Pharmacodyn; 2023 Apr; 50(2):123-132. PubMed ID: 36617366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization.
    Ette EI; Onyiah LC
    Eur J Drug Metab Pharmacokinet; 2002; 27(3):213-24. PubMed ID: 12365204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental design and efficient parameter estimation in population pharmacokinetics.
    al-Banna MK; Kelman AW; Whiting B
    J Pharmacokinet Biopharm; 1990 Aug; 18(4):347-60. PubMed ID: 2231324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of animal pharmacokinetic data: performance of the one point per animal design.
    Ette EI; Kelman AW; Howie CA; Whiting B
    J Pharmacokinet Biopharm; 1995 Dec; 23(6):551-66. PubMed ID: 8733946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of pharmacokinetic parameters by orthogonal regression: comparison of four algorithms.
    Tod M; Aouimer A; Petitjean O
    Comput Methods Programs Biomed; 2002 Jan; 67(1):13-26. PubMed ID: 11750944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation.
    Hénin E; Tod M; Trillet-Lenoir V; Rioufol C; Tranchand B; Girard P
    Clin Pharmacokinet; 2009; 48(6):359-69. PubMed ID: 19650675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A note on population pharmacokinetic studies with a single sampling design.
    Narukawa M; Yafune A
    Ther Drug Monit; 2005 Apr; 27(2):111-5. PubMed ID: 15795638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of multiple-trough sampling design and algorithm on the estimation of population and individual pharmacokinetic parameters].
    Ling J; Qian LX; Ding JJ; Jiao Z
    Yao Xue Xue Bao; 2014 May; 49(5):686-94. PubMed ID: 25151742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.
    Tod M; Rocchisani JM
    J Pharmacokinet Biopharm; 1997 Aug; 25(4):515-37. PubMed ID: 9561492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.
    White DB; Walawander CA; Tung Y; Grasela TH
    J Pharmacokinet Biopharm; 1991 Feb; 19(1):87-112. PubMed ID: 2023111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.